TD Cowen Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its target price reduced by analysts at TD Cowen from $25.00 to $23.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. TD Cowen’s price target points to a potential upside of 16.02% from the stock’s current price.

Several other equities analysts have also recently weighed in on the company. Leerink Partners raised their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research report on Monday, March 9th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, March 10th. Finally, Truist Financial restated a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $31.71.

Hims & Hers Health Price Performance

HIMS traded down $1.04 during trading on Friday, hitting $19.83. 7,347,645 shares of the company traded hands, compared to its average volume of 34,211,336. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The company has a market cap of $4.52 billion, a PE ratio of 38.90, a P/E/G ratio of 2.41 and a beta of 2.55. The stock’s 50-day simple moving average is $21.97 and its two-hundred day simple moving average is $36.08. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.11 EPS. As a group, sell-side analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the sale, the insider directly owned 8,752 shares of the company’s stock, valued at $216,086.88. The trade was a 38.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Chi sold 97,289 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the completion of the sale, the chief operating officer owned 407,282 shares of the company’s stock, valued at $10,055,792.58. The trade was a 19.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 134,984 shares of company stock worth $3,458,041 over the last three months. 13.71% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of HIMS. Pathway Capital Management LP acquired a new position in shares of Hims & Hers Health during the third quarter valued at about $6,766,000. Steadview Capital Management LLC grew its position in Hims & Hers Health by 80.0% during the 3rd quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock worth $39,809,000 after purchasing an additional 311,845 shares during the last quarter. Farallon Capital Management LLC increased its stake in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State of Michigan Retirement System raised its holdings in shares of Hims & Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after buying an additional 678,600 shares during the last quarter. Finally, BIT Capital GmbH lifted its stake in shares of Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after buying an additional 938,728 shares during the period. Institutional investors own 63.52% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims announced availability of a broad lineup of Novo Nordisk FDA‑approved GLP‑1s (including Wegovy® and Ozempic) to eligible customers, expanding HIMS’s addressable market, product mix and potential ARPU upside. Read More.
• Positive Sentiment: Market commentary and analyst writeups argue the Novo settlement removed a key legal overhang and clears the path to sell branded drugs — a structural catalyst for revenue and margin improvement. Read More.
• Positive Sentiment: Recent earnings momentum (an EPS beat and strong subscriber/revenue growth) has driven a multi‑week rally, supporting the view that fundamentals are improving after the litigation resolution. Read More.
• Neutral Sentiment: Coverage highlights a strategic shift toward a broader branded GLP‑1 and telehealth mix following the Novo deal — potentially positive long‑term but execution‑dependent in the near term. Read More.
• Neutral Sentiment: Marketing and sponsored features position the brand in consumer channels (helpful for awareness) but are not immediate earnings drivers. Read More.
• Negative Sentiment: An analyst price target was cut (reported ~14.6% lower), which lowers street expectations and can prompt profit‑taking after the recent run. Read More.
• Negative Sentiment: Shareholder litigation: the Schall Law Firm opened a securities‑fraud investigation into HIMS, adding legal/regulatory risk that can keep sentiment subdued until resolved. Read More.
• Negative Sentiment: Insider selling: the CFO disclosed a ~9.2k‑share sale in March, and persistent insider dispositions have been cited as a sentiment headwind. Read More.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.